Align Technology, Inc. (ALGN)

Verve Therapeutics Stock Forecast

Stock Price Forecast

The 12 analysts that cover Verve Therapeutics stock have a consensus rating of "Buy" and an average price target of $216.25, which forecasts a 58.40% increase in the stock price over the next year. The lowest target is $154 and the highest is $280.

Price Target: $216.25 (+58.40%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$154	$216.25	$206	$280
Change	+12.80%	+58.40%	+50.89%	+105.10%

Analyst Ratings

The average analyst rating for Verve Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	2	2	2	2	2	2
Buy	6	7	7	7	7	6
Hold	2	2	3	3	3	4
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	11	12	13	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Block Stifel	Stifel	Strong Buy Maintains $275 → $200	Strong Buy	Maintains	$275 → $200	+46.50%	Jul 31, 2025
Vik Chopra Wells Fargo	Wells Fargo	Buy Maintains $246 → $199	Buy	Maintains	$246 → $199	+45.77%	Jul 31, 2025
Jason Bednar Piper Sandler	Piper Sandler	Buy Maintains $250 → $190	Buy	Maintains	$250 → $190	+39.17%	Jul 31, 2025
Erin Wright Morgan Stanley	Morgan Stanley	Buy → Hold Downgrades $249 → $154	Buy → Hold	Downgrades	$249 → $154	+12.80%	Jul 31, 2025
Vik Chopra Wells Fargo	Wells Fargo	Buy Maintains $255 → $246	Buy	Maintains	$255 → $246	+80.19%	May 1, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

4.23B

Increased by 5.78%

from 4.00B

Revenue Next Year

4.47B

Increased by 5.63%

from 4.23B

EPS This Year

10.50

Increased by 86.87%

from 5.62

EPS Next Year

11.47

Increased by 9.21%

from 10.50

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	2.47B	3.95B	3.73B	3.86B	4.00B	4.23B	4.47B	4.73B
Revenue Growth	2.71%	59.90%	-5.51%	3.42%	3.54%	5.78%	5.63%	5.80%
EPS	22.41	9.69	4.61	5.81	5.62	10.50	11.47	12.68
EPS Growth	305.24%	-56.76%	-52.43%	26.03%	-3.27%	86.87%	9.21%	10.58%
Forward PE	-	-	-	-	-	13.00	11.90	10.76
No. Analysts	-	-	-	-	-	22	21	14

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	4.4B	4.7B	5.0B
Avg	4.2B	4.5B	4.7B
Low	4.0B	4.2B	4.4B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	9.8%	11.3%	12.1%
Avg	5.8%	5.6%	5.8%
Low	0.3%	-0.8%	-1.9%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	10.95	12.03	13.44
Avg	10.50	11.47	12.68
Low	9.98	10.60	11.88

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	94.8%	14.6%	17.2%
Avg	86.9%	9.2%	10.6%
Low	77.5%	1.0%	3.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.